What type of study is this?

This is a Phase 2 study (also classified as: Observational).

Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial shows MRD status predicts outcomes in multiple myeloma patients on lenalidomide maintenance, suggesting immune factors play a role.

Patients with MRD resurgence had worse progression-free survival compared to those with sustained MRD-negativity, highlighting the importance of MRD status.
At 1 and 2 years, significant differences were noted in outcomes, with PFS rates of 0.036 and 0.0014 respectively for MRD-positive patients.
This single-arm trial assessed patients undergoing continuous lenalidomide maintenance, revealing insights into immune response through T cell profiling.
Results suggest that immune-MRD status can inform treatment strategies for multiple myeloma, calling attention to patient-specific profiles.

Firestone et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 2 trial shows MRD status predicts outcomes in multiple myeloma patients on lenalidomide maintenance, suggesting immune factors play a role.